XTNT Form 4 shows director DSU grant and updated share holdings

Rhea-AI Filing Summary

Xtant Medical Holdings (XTNT) reported an insider equity grant to a director dated November 15, 2025. The director received 158,228 deferred stock units (DSUs) of common stock at a stated price of $0 under the company’s Amended and Restated 2023 Equity Incentive Plan. Following this grant, the director beneficially owned 517,619 shares directly, including 465,570 shares issuable upon settlement of DSUs, and 1,015,272 shares indirectly through The Platinum Legacy Trust. The new DSU award will vest on November 15, 2026 if the director remains on the board, with settlement of the underlying shares deferred under the DSU award agreement.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Beeson Jonn R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	158,228	$0.00	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 517,619 shares (Direct); Common Stock — 1,015,272 shares (Indirect, The Platinum Legacy Trust, dated February 24, 2017, Jonn R. Beeson, Trustee)

Footnotes (1)

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock. Includes 465,570 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Beeson Jonn R.

(Last) (First) (Middle)

C/O XTANT MEDICAL HOLDINGS, INC.

664 CRUISER LANE

(Street)

BELGRADE MT 59714

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xtant Medical Holdings, Inc. [ XTNT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/15/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/15/2025		A		158,228(1)	A	$0	517,619(2)	D
Common Stock								1,015,272	I	The Platinum Legacy Trust, dated February 24, 2017, Jonn R. Beeson, Trustee

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares are subject to a deferred stock unit (DSU) award granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan and will vest on November 15, 2026, conditioned upon the Reporting Person remaining a director of Xtant through the vesting date. The settlement of the vested shares underlying the DSU award has been deferred and will occur at a later date pursuant to the terms of the DSU award agreement. Each DSU represents a contingent right to receive one share of the Issuer's common stock.

2. Includes 465,570 shares issuable upon settlement of deferred stock units granted under the Xtant Medial Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan, conditioned upon the Reporting Person remaining a director of Xtant through the respective vesting dates.

	/s/ Amy Culbert, attorney-in-fact	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Xtant Medical Holdings (XTNT) report in this Form 4?

The filing reports that a director of Xtant Medical Holdings (XTNT) received a grant of 158,228 deferred stock units (DSUs) of common stock on November 15, 2025 under the company’s Amended and Restated 2023 Equity Incentive Plan.

When do the newly granted 158,228 DSUs for the Xtant (XTNT) director vest?

The 158,228 DSUs will vest on November 15, 2026, provided the reporting person remains a director of Xtant Medical Holdings through that vesting date.

How many Xtant (XTNT) shares does the director beneficially own after this transaction?

After the reported grant, the director beneficially owns 517,619 shares directly, which includes 465,570 shares issuable upon settlement of DSUs, and an additional 1,015,272 shares indirectly through The Platinum Legacy Trust.

What is a deferred stock unit (DSU) in the context of Xtant Medical (XTNT)?

Each deferred stock unit (DSU) represents a contingent right to receive one share of Xtant’s common stock. The shares underlying the DSUs are delivered later, according to the DSU award agreement terms.

Does the Xtant (XTNT) director pay anything for the 158,228 DSUs reported?

The DSUs were reported with a stated price of $0 per share, indicating the grant was an equity award rather than an open-market purchase.

Under which plan were the Xtant Medical (XTNT) DSUs granted to the director?

The 158,228 DSUs were granted under the Xtant Medical Holdings, Inc. Amended and Restated 2023 Equity Incentive Plan.